報價延遲最少15分鐘:2026/05/16 14:10 EDT
常規時段
|
|
|
|
|
||||||||||||
|
|
|
|
|
199.74 
|
|
|
| 價值評估 |
|
盈利(現時/預測)
10.71/18.41
|
|
企業價值
24.70B
|
| 資產負債 |
|
每股賬面淨值
-11.77
|
| 現金流量 |
|
現金流量率
0.14
|
| 損益表 |
|
收益
13.64B
|
|
每股收益
185.58
|
|
同行比較
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. |
